Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia
Open Access
- 1 November 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 108 (9) , 2937-2941
Abstract
Heparin-induced thrombocytopenia (HIT) is caused by antibodies against a “self” protein—platelet factor 4—bound to heparin. We observed an overrepresentation of the female gender in 290 patients who developed HIT after cardiac or orthopedic surgery compared with the representation found in national databases (study 1). Therefore, we investigated gender imbalance in HIT by logistic regression analysis of a randomized controlled trial of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) (study 2), and we analyzed individual patient data from 7 prospective studies comparing HIT frequency between UFH and LMWH, evaluating effects of gender, heparin (UFH vs LMWH), and patient type (surgical vs medical) (study 3). All 3 studies showed female overrepresentation, which for study 3 was a common odds ratio (OR) of 2.37 (95% confidence interval [95% CI], 1.37-4.09; P = .0015). Study 3 also showed an interaction between gender, heparin, and patient type. Although UFH was more likely than LMWH to cause HIT (P < .0001), this effect was predominantly seen in women compared with men (common OR, 9.22 vs 1.83; P = .020) and in surgical patients compared with medical patients (common OR, 13.93 vs 1.75; P = .005). We conclude that females are at greater risk for HIT and that using LMWH to prevent HIT may have greatest absolute benefit in females undergoing surgical thromboprophylaxis.Keywords
This publication has 41 references indexed in Scilit:
- Lepirudin in patients with heparin-induced thrombocytopenia – results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3Journal of Thrombosis and Haemostasis, 2005
- Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopeniaBlood, 2005
- Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosisThrombosis and Haemostasis, 2005
- Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopeniaBlood, 2005
- The homozygous FcγRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexesBlood, 2004
- How I treat heparin-induced thrombocytopenia and thrombosisBlood, 2003
- Potential role of platelet FcγRIIA in collagen-mediated platelet activation associated with atherothrombosisAtherosclerosis, 2002
- Gefahrenpotentiale in der medikamentösen Thromboseprophylaxe - niedermolekuläre Heparine versus StandardheparinZeitschrift für Orthopädie und ihre Grenzgebiete, 1999
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995
- Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.BMJ, 1991